1. Market Research
  2. > Pharmaceutical Market Trends
  3. > South Korea Pharmaceuticals and Healthcare Report Q2 2016

South Korea Pharmaceuticals and Healthcare Report Q2 2016

  • April 2016
  • -
  • Business Monitor International
  • -
  • 112 pages

Includes 3 FREE quarterly updates

BMI View: South Korea will remain an important market for innovative pharmaceutical firms in the AsiaPacific. While the country's designation as a 'Watch List' country in PhRMA's 2016 submission highlightsconcerns over the regulatory environment, this is an improvement from 2015 and reflects ongoing progress.Consequently, we maintain our outlook that multinational pharmaceutical investments into the country willremain strong, with strong upside risks from the possible participation of South Korea in the Trans-PacificPartnership deal.

Headline Expenditure Projections

- Pharmaceuticals: KRW17,117.1bn (USD15.1bn) in 2015 to KRW17,693.8bn (USD14.1bn) in 2016;+3.4% in local currency terms and -6.8% in US dollar terms. Forecast in USD terms is influenced byexchange rate.

- Healthcare: KRW113,990.2bn (USD100.8bn) in 2015 to KRW120,624.8bn (USD96.1bn) in 2016;+5.8% in local currency terms and -4.6% in US dollar terms. Forecast in USD terms is influenced byexchange rate.

Table Of Contents

South Korea Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (South Korea 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Latest Updates 11
Structural Trend 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (South Korea 2012-2020) 12
Healthcare Market Forecast 14
Latest Updates 14
Structural Trends 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2012-2020) 17
Prescription Drug Market Forecast 18
Structural Trends 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 19
Patented Drug Market Forecast 20
Structural Trends 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 21
Generic Drug Market Forecast 22
Structural Trends 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 23
OTC Medicine Market Forecast 24
Structural Trends 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 27
Pharmaceutical Trade Forecast 28
Structural Trends 28
Table: Pharmaceutical Trade Data And Forecasts (South Korea 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (South Korea 2014-2020) 30
Industry Risk Reward Ratings 31
Asia Pacific Risk/Reward Index 31
South Korea Risk/Reward Ratings 37
Rewards 37
Risks 37
Regulatory Review 39
Regulatory Review 39
Intellectual Property Issues 39
Pricing And Reimbursement Regime 40
Table: Different Price Control Levers 40
Market Overview 46
Market Overview 46
Healthcare System 46
Table: Healthcare Resources (South Korea 2010-2015) 47
Table: Healthcare Personnel (South Korea 2010-2015) 47
Table: Healthcare Activity (South Korea 2010-2015) 48
Healthcare Sector 48
National Health Insurance Corporation 49
Research And Development 51
Biotechnology Sector 52
Clinical Trials 54
Epidemiology 56
Competitive Landscape 59
Research-Based Industry 59
Generic Drugmakers 60
Table: Multinational Market Activity 62
Pharmaceutical Distribution 63
Pharmaceutical Retail Sector 64
Table: Pharmaceutical Retailers, 2000-10 64
Table: Timeline Of OTC Slow Liberalisation 66
Company Profile 67
Daewoong Pharmaceutical 67
Dong-A Pharmaceutical 70
Eli Lilly 75
GlaxoSmithKline 78
Hanmi Pharmaceutical Co 81
Merck and Co 84
Novartis 87
Pfizer 91
Sanofi 94
Yuhan Corporation 97
Demographic Forecast 101
Demographic Outlook 101
Table: Population Headline Indicators (South Korea 1990-2025) 102
Table: Key Population Ratios (South Korea 1990-2025) 102
Table: Urban/Rural Population and Life Expectancy (South Korea 1990-2025) 103
Table: Population By Age Group (South Korea 1990-2025) 103
Table: Population By Age Group % (South Korea 1990-2025) 104
Glossary 106
Methodology 108
Pharmaceutical Expenditure Forecast Model 108
Healthcare Expenditure Forecast Model 108
Notes On Methodology 109
Risk/Reward Index Methodology 110
Index Overview 111
Table: Pharmaceutical Risk/Reward Index Indicators 111
Indicator Weightings 112

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.